The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2010VEGF-B - A New Neurotrophic Factor for Treatment for Parkinson's Disease
Objective/Rationale:
We discovered that the vascular endothelial growth factor, VEGF-B, acts as a natural response of brain cells to a neurotoxin that produces Parkinson’s disease in pre-clinical... -
Target Validation, 2010mTORC1 as a Target for the Treatment of Levodopa-induced Dyskinesia
Objective/Rationale:
The choreic and dystonic movements, or dyskinesia, which develop in response to prolonged treatment with levodopa, represent one of the major limitations to the current therapy... -
Target Validation, 2010Peroxisome-Proliferator Activated Receptor gamma as a Target for Anti-Dyskinesia Pharmacotherapy
Objective/Rationale:
We plan to develop new pharmacological approaches to treat levodopa-induced dyskinesia (LID) in a pre-clinical model of Parkinson’s disease (PD). Preliminary data from our... -
Target Validation, 2010Targeting the Unfolded Protein Response (UPR) Transcription Factor XBP-1 to Treat Parkinson's Disease
Objective/Rationale:
Our general objective is to investigate the role of a specific component of a cellular stress responses linked to organelle damage, the Unfolded Protein Response (UPR), in the... -
Target Validation, 2010Modulation of the Rho Kinase pathway for improvement of regeneration in PD
Objective/Rationale:
A characteristic feature of Parkinson’s disease is the loss of axons, the long processes of neuronal cells. This loss of axons seems to occur early in the course of the disease... -
Rapid Response Innovation Awards, 2010SNCA Haplotyping in Parkinson's Disease and Multiple System Atrophy
Objective/Rationale:
A succinct, lay-oriented statement of the scientific rationale for this project. We have recently shown that genetic variants at the SNCA gene locus, coding for the alpha-synuclein...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.